albuvirtide

Peptideexperimental

Clinical trial activity

7 trials · 5 clinical orgs · 0 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Earliest trial started Jan 1, 2014 (NCT02369965)

Timeline

2010s

Jan 1, 2014
Earliest Phase 3 Sponsor(trial)
Jan 1, 2018
Earliest Phase 2 Sponsor(trial)

2020s

Jan 1, 2022
Earliest Phase 1 Sponsor(trial)

Indications

Approved for

HIV Infections

Studied for

Mechanism of action

Unspecified targetINHIBITOR
Inhibitor
UrushiolINHIBITOR
Urushiol inhibitor
Reacts with the catechol moiety of urushiol, the region of the allergen being critically important i
GP41INHIBITOR
GP41 inhibitor
- GP41 (HIV1 ENV) ↗

Chemistry & pharmacology

Loading structure…

SMILES

CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)CCN1C(=O)C=CC1=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(C)=O)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O

Mol. weight: 4667 g/mol
Chirality: Single Stereoisomer
Inorganic: No
Polymer: No
Multi-specific: No

Oral

Parenteral

Topical

Sources

ChEMBLCHEMBL4297257 ↗
ChEMBLCHEMBL2109626 ↗

Also known as

albuvirtide
albuvirtide
alg-991

Clinical trials

NCT ID	Phase	Start date	Sponsor(s)
NCT06808035	N/A	Jan 9, 2024	University of Leeds, University of Louisville, Vanderbilt University
NCT05206019	Phase 1	Feb 1, 2022	Frontier Biotechnologies Co., Ltd.
NCT04819347	Phase 2	May 1, 2021	Frontier Biotechnologies Co., Ltd.
NCT04560569	Phase 2	Dec 25, 2020	Frontier Biotechnologies Co., Ltd.
NCT04006353	Phase 4	Jul 31, 2019	Fudan University
NCT03719664	Phase 2	Dec 17, 2018	Frontier Biotechnologies Co., Ltd.
NCT02369965	Phase 3	Jan 1, 2014	Frontier Biotechnologies Co., Ltd.

Showing 7 of 7 trials

Page 1 / 1

Organizations

Research & Development (5)

Organization	Org type	Trials	As lead sponsor	Phases	Earliest year
Frontier Biotechnologies Co., Ltd.	For profit	5	5	3	2014
Fudan University	Academic/Hospital	1	1	1	2019
University of Leeds	Academic/Hospital	1	0	1	2024
University of Louisville	Academic/Hospital	1	1	1	2024
Vanderbilt University	Academic/Hospital	1	0	1	2024

5 organizations

Page 1 / 1